The human studies reviewed here concern oral oxymetholone. They do not establish that injectable oxymetholone builds more muscle, causes less liver injury or has a longer measured half-life than the oral form. The previous guide supplied route comparisons and plasma-curve assumptions without a direct human pharmacokinetic or clinical comparison of the same molecule by both routes.
What was actually administered in the human trials?
| Study | Population and administered treatment | Reported findings |
|---|---|---|
| Hengge et al., 2003, PMID 12646793 | 89 people with HIV-associated wasting; oral 50 mg twice or three times daily versus placebo for 16 weeks | Weight increased by 3.5 kg and 3.0 kg in the twice- and three-times-daily groups, versus 1.0 kg with placebo. Alanine aminotransferase increases greater than five times baseline occurred in 27%, 35% and 0% in those groups, respectively. |
| Schroeder et al., 2002, PMID 12388137 | 31 men aged 65-80; oral 50 or 100 mg daily versus placebo for 12 weeks | Lean body mass increased by 3.3 and 4.2 kg in the active groups, versus 0.0 kg with placebo. ALT increased in the 100 mg group and HDL decreased in both active groups. |
| Aramwit et al., 2009, PMID 19356374 | 44 maintenance-hemodialysis patients; oral 50 mg twice daily versus placebo for 24 weeks | Fat-free mass and insulin-resistance measures changed; two of 21 treated participants had elevated liver enzymes. |
Why the route-comparison paper does not compare injectable Anadrol
Neff et al., PMID 7010161, compared several androgens in patients on hemodialysis. Nandrolone decanoate and testosterone enanthate were given by injection; oxymetholone and fluoxymesterone were given by mouth. A better hematocrit response to the injectable drugs in that experiment does not demonstrate a better injectable form of oxymetholone. Both the molecule and the route changed.
What these numbers can and cannot answer
Each trial has a specific population, dose, duration and measured outcome. Weight, lean body mass and fat-free mass are related but different measurements. Findings in HIV wasting, older men or hemodialysis patients cannot be pooled into a bodybuilding prediction. None of these trials compares injected and oral oxymetholone at equivalent exposures.
From the FormBlends catalog
BPC-157 Oral (Stable Arginate Salt)
Acid-stable oral form of BPC-157 for gut and systemic healing · From $69/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about BPC-157 Oral (Stable Arginate Salt) →Does bypassing first-pass absorption establish lower liver risk?
It does not establish a clinical advantage in the cited oxymetholone trials. The studies document liver-test changes with oral treatment but do not measure an injectable comparator. A theoretical difference in absorption does not quantify the risk of an unstudied formulation, and changing administration route does not make the oral trial's adverse-event observations disappear.
Half-life and depot claims
The previous guide repeated an eight-to-nine-hour half-life and assigned similar elimination to both routes while speculating about an oil depot. The sources reviewed here do not provide a direct human concentration-time study of injectable oxymetholone supporting that comparison. Absorption rate, peak concentration, total exposure and elimination half-life are separate measurements. Without formulation-specific data, an injection schedule or extended-duration advantage cannot be derived from them.
Oral versus injectable evidence comparison
| Question | Oral oxymetholone | Injectable oxymetholone |
|---|---|---|
| Human clinical outcomes in the cited trials | Reported for defined patient populations | Not established by these trials |
| Liver-test observations | Reported, including comparator rates in the HIV trial | No same-molecule route comparator identified in the reviewed studies |
| Measured route-specific exposure or half-life | Not a direct comparison in these sources | No validated depot comparison in these sources |
| Proof of superior muscle gain or tolerability | Not compared with injectable oxymetholone | Not established |
Frequently asked questions
Did any of these studies use injectable oxymetholone?
No. The three oxymetholone trials summarized used oral treatment. The Neff comparison injected different androgens.
Does the HIV trial show a liver advantage for injections?
No. It compares two oral schedules with placebo and reports liver-associated toxicity. It does not compare routes.
Can the eight-to-nine-hour estimate determine an injection schedule?
Not from these studies. A measured formulation-specific exposure profile would be needed to support such a calculation.
Which route wins this comparison?
The cited evidence cannot rank the two routes for the same molecule. Oral trial results do not fill the missing injectable comparison.
Sources
- Hengge et al.: oral oxymetholone in HIV-associated wasting
- Schroeder et al.: oral oxymetholone in older men
- Aramwit et al.: oral oxymetholone in maintenance hemodialysis
- Neff et al.: different androgens and routes for dialysis-associated anemia
Ready when you are
BPC-157 Oral (Stable Arginate Salt)
Acid-stable oral form of BPC-157 for gut and systemic healing · From $69/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
Learn about BPC-157 Oral (Stable Arginate Salt) →